[{"orgOrder":0,"company":"SHIRE LLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"Phosphotransferase pUL97 | Serine\/threonine-protein kinase BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SHIRE LLC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SHIRE LLC \/ SHIRE LLC","highestDevelopmentStatusID":"15","companyTruncated":"SHIRE LLC \/ SHIRE LLC"}]

Find Clinical Drug Pipeline Developments & Deals by SHIRE LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.

                          Product Name : Livtencity

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 21, 2021

                          Lead Product(s) : Maribavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Takeda Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank